Johnson & Johnson, Novartis AG and Takeda Pharmaceutical Co Ltd have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA, two people with knowledge of the matter said on Monday.
The owners of investment vehicles Igarapava Participações SA and Maiorem SA de CV, which hold a combined 34 percent of Hypermarcas, hired Banco Bradesco SA and Credit Suisse Group AG to advise them on options for their stakes, including a sale, said the people.
According to one of the people, who requested anonymity because the matter is private, the purchase of the stakes that Brazilian billionaire João Alves Queiroz Filho and the Mexican family that own Igarapava and Maiorem, respectively, would automatically trigger a buyout of minority shareholders.
Shares of Hypermarcas closed 3.8 percent up at 30.35 reais on Monday, on optimism that a deal could boost the company’s $6 billion market value. The stock had extended gains after the Reuters report, rising more than 7 percent to an all-time high of 31.38 reais.
None of the potential bidders have yet delivered formal, binding proposals, one of the people said, noting that there is no certainty a deal will be struck.
In a securities filing, Hypermarcas was informed by the investors in those vehicles about “the inexistence of any attempts to sell their stakes in the company.” The banks and Takeda did not immediately have a comment.
J&J and Novartis declined to comment on market speculation.
Interest in Hypermarcas from foreign pharmaceutical behemoths comes after Brazil’s largest listed drug producer spent the past two years focusing on over-the-counter medicines. Hypermarcas raised some $1.5 billion from the sale of personal care brands to Coty Inc, Reckitt Benckiser Group Plc and Ontex Group NV.
O Globo columnist Lauro Jardim reported on Sunday, without citing how he obtained the information, that billionaire tycoon Queiroz and his family were discussing a potential sale of their stakes with a number of unidentified foreign companies.
By Tatiana Bautzer and Guillermo Parra-Bernal
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.